Abstract:Anxiety disorders are prevalent and disabling yet understudied from a genetic standpoint, compared with other major psychiatric disorders such as bipolar disorder and schizophrenia. The fact that they are more common, diverse and perceived as embedded in normal life may explain this relative oversight. In addition, as for other psychiatric disorders, there are technical challenges related to the identification and validation of candidate genes and peripheral biomarkers. Human studies, particularly genetic ones, are susceptible to the issue of being underpowered, because of genetic heterogeneity, the effect of variable environmental exposure on gene expression, and difficulty of accrual of large, well phenotyped cohorts. Animal model gene expression studies, in a genetically homogeneous and experimentally tractable setting, can avoid artifacts and provide sensitivity of detection. Subsequent translational integration of the animal model datasets with human genetic and gene expression datasets can ensure cross-validatory power and specificity for illness. We have used a pharmacogenomic mouse model (involving treatments with an anxiogenic drug—yohimbine, and an anti-anxiety drug—diazepam) as a discovery engine for identification of anxiety candidate genes as well as potential blood biomarkers. Gene expression changes in key brain regions for anxiety (prefrontal cortex, amygdala and hippocampus) and blood were analyzed using a convergent functional genomics (CFG) approach, which integrates our new data with published human and animal model data, as a translational strategy of cross-matching and prioritizing findings. Our work identifies top candidate genes (such as FOS, GABBR1, NR4A2, DRD1, ADORA2A, QKI, RGS2, PTGDS, HSPA1B, DYNLL2, CCKBR and DBP), brain–blood biomarkers (such as FOS, QKI and HSPA1B), pathways (such as cAMP signaling) and mechanisms for anxiety disorders—notably signal transduction and reactivity to environment, with a prominent role for the hippocampus. Overall, this work complements our previous similar work (on bipolar mood disorders and schizophrenia) conducted over the last decade. It concludes our programmatic first pass mapping of the genomic landscape of the triad of major psychiatric disorder domains using CFG, and permitted us to uncover the significant genetic overlap between anxiety and these other major psychiatric disorders, notably the under-appreciated overlap with schizophrenia. PDE10A, TAC1 and other genes uncovered by our work provide a molecular basis for the frequently observed clinical co-morbidity and interdependence between anxiety and other major psychiatric disorders, and suggest schizo-anxiety as a possible new nosological domain.

Unraveling COVID-19 relationship with anxiety disorders and symptoms using genome-wide data

Genetic analyses point to alterations in immune-related pathways underpinning the association between psychiatric disorders and COVID-19

Meta-analyses of genome-wide linkage scans of anxiety-related phenotypes

Leveraging Large-Scale Genetic Data to Assess the Causal Impact of COVID-19 on Multisystemic Diseases

Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study

Comorbidity alters the genetic relationship between anxiety disorders and major depression

Gene Discovery and Biological Insights into Anxiety Disorders from a Multi-Ancestry Genome-wide Association Study of >1.2 Million Participants

Identification of novel genomic loci for anxiety symptoms and extensive genetic overlap with psychiatric disorders

Genome-wide association studies in non-anxiety individuals identified novel risk loci for depression

Investigating the shared genetic architecture between COVID-19 and obesity: a large-scale genome wide cross-trait analysis

Mapping the human genetic architecture of COVID-19

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms

Combined effects of inflammation and coronavirus disease 2019 (COVID‐19) on the risks of anxiety and depression: A cross‐sectional study based on UK Biobank

Symptom-level modelling unravels the shared genetic architecture of anxiety and depression

Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID‐19 outcomes: genome‐wide cross trait analysis and bi‐directional Mendelian randomization study

The effect of polygenic liability to mental disorders on COVID-19 outcomes in people with depression: the mediating role of anxiety

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

Causal role of immune cells in generalized anxiety disorder: Mendelian randomization study

Identification of Genetic Loci Jointly Influencing COVID-19 and Coronary Heart Diseases

Genetic Predispositions to Psychiatric Disorders and the Risk of COVID-19

Positive and negative affect, related mental health traits, and cognitive performance: shared genetic architecture and potential causality